Arbutus Q1 FY26 net income turns to USD 169.7 million; revenue rises to USD 179.1 million

Arbutus Biopharma
Moderna

Arbutus Biopharma

ABUS

0.00

Moderna

MRNA

0.00
  • Arbutus Biopharma Q1 2026 revenue more than doubled to USD 179.1 million, driven by USD 178.7 million in estimated license revenue tied to Genevant’s Moderna litigation settlement.
  • Net income swung to USD 169.7 million, or USD 0.88 per share, from a loss a year earlier.
  • R&D expense fell 53.33% to USD 4.1 million, while G&A expense edged up 0.98% to USD 5.9 million.
  • Cash, cash equivalents and marketable securities rose to USD 95.2 million at March 31, 2026.
  • FDA granted Fast Track designation for imdusiran for chronic hepatitis B; Moderna is set to pay USD 950 million upfront in July 2026, with an additional USD 1.3 billion contingent on an appellate ruling.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130730PRIMZONEFULLFEED9718838) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.